Zymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) for $17.00 per share in cash, representing an equity ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE